Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00880711
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 57
Inclusion Criteria
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
- Ability to read and write and complete questionnaires
- Provision of written informed consent
- Patients who already received a prescription for fulvestrant
Exclusion Criteria
- A subject who does not fulfil all the above mentioned inclusion criteria is not allowed to participate in this NIS
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Benefit, defined as the development of at least one of the following stages and holding on for at least 6 month: Complete response, partial response or stable disease Baseline, after 3, 6, 9 month
- Secondary Outcome Measures
Name Time Method Tolerability After 3, 6, 9 month (as per usual clinical practice) Quality of Life Baseline, after 3, 6, 9 month (as per usual clinical practice) Performance status (Karnofsky Index) Baseline, after 3, 6, 9 month (as per usual clinical practice)
Trial Locations
- Locations (1)
Research Site
🇦🇹Wr. Neustadt, Austria